In the clinical management of diabetes and metabolic disorders, precision is the cornerstone of therapeutic efficacy. According to the rigorous consensus standards established by the NGSP and IFCC, any HbA1c POCT platform must maintain a coefficient of variation (CV) ≤3.0% to ensure clinical validity for reliable glycemic monitoring and long-term diagnostic screening.

JIEZLAB Diagnostics is leading this high-precision paradigm shift with its highly portable, user-friendly, and multi-indicator integrated Point-of-Care HbA1c testing system. Widespread post-market deployment and ongoing end-user evaluations provide unequivocal real-world validation for the JIEZLAB HbA1c system. Large-scale method comparison studies were conducted against the industry's benchmark platforms, yielding outstanding correlation results across all therapeutic ranges:

JIEZLAB (Model: JIE-100) vs. Benchmark HbA1c POCT system: 

Across multiple independent clinical trials, JIEZLAB system demonstrated unwavering consistency against benchmark HbA1c POCT system:

• Trial 1 [Shanghai, China]: Achieved an exceptional linear correlation of r= 0.9957, with a negligible mean bias.

• Trial 2 [Shandong, China]: An excellent linear correlation (r=0.9966) was achieved, accompanied by negligible mean bias.

JIEZLAB (Model: JIE-100) vs. Gold-Standard Laboratory HPLC System: 

As illustrated in the figure, the coefficient of correlation (r) for HbA1c measurements between the JIEZLAB and Laboratory HPLC System reaches 0.9961, indicating an excellent correlation between the two analytical systems.

Ultimately, this robust pool of real-world evidence confirms that JIEZLAB Point-of-Care HbA1c testing consistently maintains a strict CV ≤3.0%. By delivering laboratory-grade analytical precision directly from a 5μL fingerstick blood within 6.5 minutes, JIEZLAB platform fully complies with the rigorous requirements set by global clinical guidelines—successfully bridging the gap between rapid decentralized testing and gold-standard laboratory performance for reliable long-term diabetes management.

Meeting these stringent clinical standards is merely our baseline. What positions the JIEZLAB HbA1c POCT analyzer as the premier choice for global primary care networks is a robust technical architecture engineered to eliminate operational bottlenecks through uncompromised quality

1.  Tubing-Free Architecture for Zero Fluidic Maintenance

 Leveraging advanced Lab-on-a-Chip microfluidics, the entire fluidic pathway is fully integrated onto a single disposable HbA1c microfluidic cartridge, eliminating complex maintenance.

 2.  5μL Fingerstick Blood End-to-End Detection 

Only 3-step workflow: Step 1: Release the embedded diluent; Step 2: Load the 5μL fingerstick blood; Step 3: Insert the cartridge into the analyzer.

 3.  Patented Dry Reagent Technology for Maximum Stability 

Supports 2 to 25°C storage and transport, ensuring uncompromised analytical performance during extended international transit

 4.  All-in-One Chronic Disease Hub

Features an extensive menu—including HbA1c, Glucose & Lipids, Liver/Kidney Function, Inflammation (CRP + SAA), and Urine ACR—on a single analyzer, perfectly fulfilling the unmet market demands of primary healthcare institutions.

5.  3 Samples per Run in 6.5 minutes

JIEZLAB stands at the forefront of chronic disease management, integrating gold-standard diagnostic precision with the structural reliability required to empower global healthcare networks.

Transform your clinical workflow today.

Whether you are looking to elevate facility performance with a premium HbA1c POCT system or establish high-value strategic partnerships, our team is ready to support your regional growth. Please contact us for product evaluations, clinical performance white papers, or global cooperation opportunities:

Corporate Email: info@jiezlab.com

Official Website: www.en.jiezibio.com